The FDA has approved the first generic versions of Requip (ropinirole hydrochloride) tablets for the treatment of moderate to severe Restless Legs Syndrome. Requip tablets have been approved in the 0.25 milligram, 0.5 milligram, 1 milligram, 2 milligram, 3 milligram, and 4 milligram dosages. Roxane Laboratories Inc., Teva Pharmaceuticals USA, Par Pharmaceuticals Inc., and Mylan Pharmaceuticals Inc. have received approval to market the ropinirole hydrochloride tablets.

A new study has shown that pramipexole (Mirapexin®/Sifrol®) can significantly reduce sleep disturbance, often the most troublesome symptom experienced by people with Restless Legs Syndrome (RLS). The important finding, presented at the 60th Annual Meeting of the American Academy of Neurology (AAN) in Chicago, U.S.A., highlights the benefit of an RLS treatment, which effectively targets the core symptoms of the condition, such as an uncontrollable urge to move the legs, as well as secondary symptoms, including sleep disturbance.